抗精神病藥物 投與時 抗파킨슨 製劑의 豫防的 併用 投與에 關한 評價

Evaluation of the Prophylactic Use of Antiparkinsonian Drug in Patients Treated with Antipsychotics

A double-blind four-week study of 46 psychotic patients who were newly admitted and treated with antipsychotic drug evaluated the need for the prophylactic use of antiparkinsoian medication. The results were as follows : 1) Of the 28 subjects in placebo group, 16(57%) developed severe EPS necessitating early termination and none of the 18 subjects in antiparknisonian group(P<0.00l). 2) The difference in incidence of EPS between placebo group(82%) and antiparkinsonian group(72 %) was statistically non-significant. 3) The difference in early termination rate among the drugs was statistically non-significant. 4) Of the 16 subjects necessitating early termination, 8(50%) developed severe EPS within first weeks. 5) 12(43% ) of the 28 subjects in the placebo group were not thought to require the prophylactic use of antiparkinsonian drug because they showed no (18%) or mild tolerable EPS (25%). We concluded that the prophylactic use of antiparkinsonian drug was needed in most patients to counteract severe EPS who became to be treated with antipsychotics for the first time or retreated after more than one month’ s duration of wash-out in spite of other side effects except EPS.